NFKB2 anticorps (AA 848-874)

N° du produit ABIN3032044

Détail du produit anti-NFKB2 anticorps

Antigène: NFKB2 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))

Épitope: AA 848-874

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NFKB2 est non-conjugé

Application: Western Blotting (WB), ELISA

Réactivité croisée (Details): Expected species reactivity: Mouse

Purification: Antigen affinity purified

Immunogène: A portion of amino acids 848-874 from the human protein was used as the immunogen for this NFKB2 antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the NFKB2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the NFKB2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur NFKB2

Antigène: NFKB2 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))

Autre désignation: NFKB2 (NFKB2 Produits)

Synonymes: anticorps NF-kappaB2, anticorps lyt, anticorps p49, anticorps p49/p100, anticorps p50B, anticorps p52, anticorps nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100, anticorps Nfkb2

Sujet: NF-kappa-B has been detected in numerous cell types that express cytokines, chemokines, growth factors, cell adhesion molecules, and some acute phase proteins in health and in various disease states. NF-kappa-B is activated by a wide variety of stimuli, such as cytokines, oxidant-free radicals, inhaled particles, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NF-kappa-B has been linked to inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis, and AIDS. In contrast, complete and persistent inhibition of NF-kappa-B has been linked directly to apoptosis, inappropriate immune cell development, and delayed cell growth. NFKB1 (MIM 164011) and NFKB2 encode p105 and p100 proteins that are processed to produce the active p50 and p52 NF-kappa-B subunits, respectively. However, the p100 and p105 proteins serve regulatory functions and should not be considered exclusively as precursor forms. The most abundant activated form of NF-kappa-B is a heterodimer of the p50 or p52 subunit bound to the RELA subunit (MIM 164014). Other NF-kappa-B complexes, consisting of hetero- and homodimers of p50, p52, RELA, REL (MIM 164910), and RELB (MIM 604758), have also been detected. NF-kappa-B complexes are inhibited by I-kappa-B proteins, NFKBIA (MIM 164008) or NFKBIB (MIM 604495), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by the kinases IKBKA (CHUK, MIM 600664) or IKBKB (MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. The activated NF-kappa-B complex translocates into the nucleus and binds DNA at kappa-B-binding motifs, such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T, R is an A or G purine, and Y is a C or T pyrimidine). For reviews, see Chen et al. (1999) [PubMed 9895331] and Baldwin (1996) [PubMed 8717528].

UniProt: Q00653

Pathways: Toll-Like Receptors Cascades